BioCryst launches Phase 1 trial for HAE candidate

DURHAM - Drug developer BioCryst Pharmaceuticals started a new multi-million-dollar trial to test the safety of its drug that treats hereditary angioedema.

The trial should be completed by mid-summer at which point BioCryst (Nasdaq: BCRX) will have safety data from human patients after the Phase 1 trial. The company estimates the trial will cost in the low single-digit millions. The exact figure is unknown because the number of cohorts has not been determined.